Evidence map›Paper›PMID 39028674›Full record

ArticleThe Journal of antimicrobial chemotherapy2024

HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21.

Lavinia Fabeni, Daniele Armenia, Isabella Abbate, Roberta Gagliardini, Valentina Mazzotta, Ada Bertoli, William Gennari, Federica Forbici, Giulia Berno, Lorenzo Piermatteo and 18 more

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Lavinia FabeniLaboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Daniele ArmeniaDepartmental Faculty, UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy.
Isabella AbbateLaboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Roberta GagliardiniClinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Valentina MazzottaClinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Ada BertoliLaboratory of Virology, Department of Laboratory Medicine, University Hospital Tor Vergata, Rome, Italy.
William GennariMolecular Microbiology and Virology Unit, Department of Laboratory Medicine and Pathological Anatomy, Policlinic of Modena, University of Modena and Reggio Emilia, Modena, Italy.
Federica ForbiciLaboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Giulia BernoLaboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Lorenzo PiermatteoDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Vanni BorghiDepartment of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.
Carmela PinnettiClinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Alessandra VergoriClinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.ORCID 0000-0001-6944-0686
Annalisa MondiClinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Giustino ParrutiInfectious Diseases Unit, Pescara General Hospital, Pescara, Italy.
Fiorella Di SoraUnit of Clinical Immunology, San Giovanni Addolorata Hospital, Rome, Italy.
Marco IannettaDepartment of Infectious Diseases, University Hospital Tor Vergata, Rome, Italy.
Miriam LichtnerInfectious Diseases Unit, Santa Maria Goretti Hospital, Sapienza University of Rome, Polo Pontino, Latina, Italy.
Alessandra LatiniSexually Transmitted Infection/Human Immunodeficiency Virus Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Cristina MussiniDepartment of Infectious Diseases, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy.
Loredana SarmatiDepartment of Infectious Diseases, University Hospital Tor Vergata, Rome, Italy.ORCID 0000-0003-1452-0333
Carlo Federico PernoMicrobiology and Diagnostic Immunology Unit, Department of Diagnostic and Laboratory Medicine, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy.
Enrico GirardiScientific Direction, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.ORCID 0000-0001-8182-5896
Andrea AntinoriClinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Fabrizio MaggiLaboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy.
Maria Mercedes SantoroDepartment of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Italian HIV Drug Resistance Group

Funding

AVIRALIA FoundationFondazione Aviralia
6 · The paper itself

Abstract

backgroundTransmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care.

methodsOverall, 2386 HIV-1 protease/reverse transcriptase and 1831 integrase sequences from drug-naïve individuals diagnosed in north and central Italy between 2015 and 2021 were analysed. TDR was evaluated over time. Phylogeny was generated by maximum likelihood. Factors associated with TDR were evaluated by logistic regression.

resultsIndividuals were mainly male (79.1%) and Italian (56.2%), with a median (IQR) age of 38 (30-48). Non-B infected individuals accounted for 44.6% (N = 1065) of the overall population and increased over time (2015-2021, from 42.1% to 51.0%, P = 0.002). TDR prevalence to any class was 8.0% (B subtype 9.5% versus non-B subtypes 6.1%, P = 0.002) and remained almost constant over time. Overall, 300 transmission clusters (TCs) involving 1155 (48.4%) individuals were identified, with a similar proportion in B and non-infected individuals (49.7% versus 46.8%, P = 0.148). A similar prevalence of TDR among individuals in TCs and those out of TCs was found (8.2% versus 7.8%, P = 0.707).By multivariable analysis, subtypes A, F, and CFR02_AG were negatively associated with TDR. No other factors, including being part of TCs, were significantly associated with TDR.

conclusionsBetween 2015 and 2021, TDR prevalence in Italy was 8% and remained almost stable over time. Resistant strains were found circulating regardless of being in TCs, but less likely in non-B subtypes. These results highlight the importance of a continuous surveillance of newly diagnosed individuals for evidence of TDR to inform clinical practice.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsPhylogenyAdultAnti-HIV AgentsFemaleGenotypeHIV ProteaseHumansItalyMaleMiddle AgedPrevalenceYoung AdultAnti-HIV AgentsHIV Protease

Identifiers

PMID39028674
PMCPMC11368429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.